Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Long-Term Extension Study of Felzartamab in Participants With Antibody-Mediated Rejection or Microvascular Inflammation Previously Enrolled in TRANSCEND or TRANSPIRE

NCT07444489 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT07444489
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07444489 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Long-Term Extension Study of Felzartamab in Participants With Antibody-Mediated Rejection or Microvascular Inflammation Previously Enrolled in TRANSCEND or TRANSPIRE
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
April 16, 2026
Completion date
December 31, 2031
Enrollment
201 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

antibody-mediated rejection, microvascular inflammation